J.P. Morgan Downgrades AstraZeneca (AZN) to Underweight
AZN Hot Sheet
Rating Summary:2 Buy, 6 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
J.P. Morgan downgrades AstraZeneca (NYSE: AZN) from Neutral to Underweight.
To see more analyst ratings on AZN Click Here.
AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
To see more analyst ratings on AZN Click Here.
AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
You May Also Be Interested In
- Basilea participates in public-private collaboration to tackle antibiotic resistance
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
